Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever FDA-approved for OSA. The basis was SURMOUNT-OSA, the first phase 3 trial of a weight-management drug against an OSA primary endpoint.
SURMOUNT-OSA was a two-arm phase 3 trial: adults with moderate-to-severe OSA (AHI ≥15) and obesity, randomized to tirzepatide vs placebo. The trial ran two parallel arms: one in patients on positive airway pressure (PAP) therapy, one in patients not using PAP.
| Endpoint | Tirzepatide | Placebo | Difference |
|---|---|---|---|
| AHI change at 52 wk (not on PAP) | −25.3 events/hr | −5.3 events/hr | −20.0 events/hr |
| AHI change at 52 wk (on PAP) | −29.3 events/hr | −5.5 events/hr | −23.8 events/hr |
| Body weight change | ~−18% | ~−2% | ~−16% |
| OSA remission rate | ~50% | ~14% | ~3.5× higher |
| Patient-reported sleepiness (ESS) | Substantially reduced | Modest reduction | Significant |
Approximately half of tirzepatide-treated patients achieved disease remission (AHI <5 or AHI 5–14 without daytime symptoms). The effect was meaningful in both PAP-using and PAP-naïve populations.
Roughly 30 million U.S. adults have OSA, and the majority remain untreated or non-adherent to PAP therapy. Until now, all OSA pharmacotherapy was off-label and mostly ineffective. SURMOUNT-OSA provides a regulator-blessed alternative for the obesity-driven subgroup.
Practical considerations:
The dominant mechanism is reduction of pharyngeal soft tissue with weight loss, but emerging hypotheses include effects on central respiratory drive, parapharyngeal fat distribution specifically, and inflammation. Weight loss is the main driver, but the effect on AHI appears larger than would be predicted from weight loss alone in older lifestyle-intervention trials.
The active ingredient effect is the same. However: (1) the FDA-approved indication is specifically for Zepbound, not compounded tirzepatide; (2) most cash-pay telehealth programs do not market OSA-specific protocols; (3) insurance coverage of Zepbound for OSA (under the December 2024 indication) is increasing and may be more affordable than cash-pay compounded for this patient population. Most OSA + obesity patients are best served by working with their sleep physician and primary care to access Zepbound through coverage when available.